Cadrenal Therapeutics, Inc. (CVKD) Stock Forecast
CVKD analyst forecast
as of October 17, 2026- Analyst consensus
- Strong buy 5.00 / 5 from 2 analysts
- Price target
- $14.00 average of analyst targets
- Upside to target
- +1,184.4% from the latest close
- Next earnings
- November 9, 2026 EPS estimate $-0.91
- 52-week range
- $0.87 – $14.13
CVKD analyst ratings
2 analystsNumber of analysts at each rating.
CVKD price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
CVKD earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.94 | −$0.94 | −$0.93 | −$1.31 | +28.6% | 2 |
| Current fiscal year (2026) | −$3.92 | −$3.92 | −$3.91 | −$6.64 | +41.0% | 2 |
| Next fiscal year (2027) | −$3.40 | −$3.55 | −$3.26 | −$3.92 | +13.0% | 2 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
CVKD revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 3 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 3 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 3 |
CVKD EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
CVKD EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$1.45 | −$2.10 | −$0.65 | −$0.94 | −$0.94 | −35.3% | 1 up · 0 down |
| Current fiscal year (2026) | −$5.88 | −$7.74 | −$3.19 | −$3.92 | −$3.92 | −33.4% | 1 up · 0 down |
| Next fiscal year (2027) | −$3.91 | −$3.91 | −$3.09 | −$3.40 | −$3.40 | −12.9% | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
CVKD earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; CVKD beat in 4 of 11.
What analysts expect from CVKD
2 analysts cover Cadrenal Therapeutics; their consensus rating is strong buy (5.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $14.00, 1,184.4% above the latest close of $1.09. Analysts expect earnings of −$3.92 per share for 2026, +41.0% from a year earlier. For 2027 the average estimate is −$3.40 per share. Cadrenal Therapeutics beat the EPS estimate in 4 of the last 11 quarters.
Related: CVKD income statement, CVKD key metrics, CVKD chart. See the CVKD stock overview for the latest quote and news.
CVKD forecast FAQ
What is Cadrenal Therapeutics's price target?
The average analyst price target for Cadrenal Therapeutics is $14.00, 1,184.4% above the latest close of $1.09.
Is Cadrenal Therapeutics a buy, hold or sell?
Of 2 analysts covering Cadrenal Therapeutics, 2 rate it a strong buy, 0 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Cadrenal Therapeutics's EPS forecast?
Analysts forecast −$3.92 per share for 2026 (range −$3.92 to −$3.91); for 2027 the estimate is −$3.40.
When does Cadrenal Therapeutics report earnings?
Cadrenal Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 9, 2026; the EPS estimate is $-0.91.
Does Cadrenal Therapeutics usually beat earnings estimates?
Cadrenal Therapeutics reported EPS at or above the analyst estimate in 4 of the last 11 quarters.